Sprycel for endometrial cancer – pro
Dasatinib, also known as Sprycel, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. It is a drug that is approved by the FDA for chronic myelogenous leukemia. It has an effect on the Src kinases, which interact with the EGFR receptor.
Studies of it to endometrial cancer are recent, early and need to be replicated and advanced. Therefore, it is still an E/I treatment. It is in a clinical trial, dasatinib Src Inhibition in Endometrial Cancer, NCT01482728.
NCCN, Enodmetrial Cancer 2018
Nautiyal J, Banerjee S, Kanwar SS, Yu Y, Patel BB, Sarkar FH, Majumdar AP. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.Int J Cancer. 2011 Feb 15;128(4):951-61.
Duska LR et al, A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.Cancer Chemother Pharmacol. 2018 Dec 8.